Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2770)	5/14/1999 5:26:00 PM
From: rkrw	Read Replies (1) \| Respond to of 10280

All, Still hold my entire position with no plans of selling. No question this latest action is negative, to what degree, we will not know for a long time. Whether there is some underlying problem with norastemizole; whether the market is simply too crowded and the drug is not distinguishing enough to merit further work; or should there be nothing wrong and Sepr is able to find another big pharma partner to move forward with, we will not know for months at the least. Part of the allure of Sepracor is that their future success is not riding on any one product. SGP is set to file the DCL NDA later this year, Sepr is bringing another 6 candidates into the clinic this year on top of their already ample pipeline. Some very good drug candidates are included within the bunch. Part of the problem with the stock hitting $140 was that the market wasn't factoring in reality and the likelihood that not all candidates would be successful. Now it is. Sepracor's annual meeting is coming up on Wednesday, I hope those who attend ask some tough questions as opposed to powderpuff's like last year. For at least the time being it looks like your hated scourge, David Maris is having the last laugh. I'm sure he'll take good advantage of the situation to issue an "I told you so" note to BS clients. Congrats to him, hopefully he'll enjoy it while it lasts.